Analysts have raised their price target for Aster DM Healthcare from ₹659 to ₹675. They cite significantly improved revenue growth prospects, which offset reduced profit margins and a lower forecast for future price-to-earnings multiples.
What's in the News
- The Board approved a final dividend of INR 1 per equity share for the financial year ended March 31, 2025. This was decided at the Annual General Meeting held on September 4, 2025 (Key Developments).
- The Ministry of Corporate Affairs approved the incorporation of "Aster DM Super-Specialty Hospital (Yeswanthpur) Private Limited" as a wholly owned subsidiary in Bengaluru, Karnataka, on July 28, 2025 (Key Developments).
- A wholly owned subsidiary named "Aster DM Super-Specialty Hospital (Sarjapur) Private Limited" was incorporated in Bengaluru, Karnataka, on July 21, 2025. The subsidiary has authorized and paid-up share capital of INR 10,00,000 (Key Developments).
- A Board Meeting was held on July 30, 2025, to consider and approve the unaudited financial results for the quarter ended June 30, 2025 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen from ₹659 to ₹675, reflecting increased confidence in company prospects.
- Discount Rate remains unchanged at 12.73%.
- Revenue Growth projection has increased significantly, from 20.87% to 44.76%.
- Net Profit Margin has fallen from 12.49% to 9.55%.
- Future P/E multiple is now expected to decrease from 56.54x to 43.72x.
Have other thoughts on Aster DM Healthcare?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.